NCT05230173 (QUOTIENT) is a NA clinical trial of Pragmatic in Ulcerative Colitis, sponsored by University of California, San Diego.

Who is sponsoring NCT05230173?

NCT05230173 is sponsored by University of California, San Diego.

What drugs are being tested in NCT05230173?

Interventions in NCT05230173: Pragmatic.

What condition does NCT05230173 study?

NCT05230173 studies Ulcerative Colitis, Crohn Disease.

Is NCT05230173 still recruiting?

NCT05230173 is currently recruiting now. Last updated 15 April 2024.

Last reviewed 2024-04-15 · How we verify

NCT05230173: QUOTIENT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission

Recruiting now NA Last updated 15 April 2024

What this trial tests

NA trial testing Pragmatic in Ulcerative Colitis in 250 participants. Currently enrolling.

Timeline

5 October 2022

Primary endpoint
1 March 2028

1 June 2028

Quick facts

Lead sponsor	University of California, San Diego
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	250
Start date	5 October 2022
Primary completion	1 March 2028
Estimated completion	1 June 2028
Sites	22 locations across United States

Drugs / interventions tested

Pragmatic

Conditions studied

Ulcerative Colitis — all drugs for Ulcerative Colitis →
Crohn Disease — all drugs for Crohn Disease →

Sponsor

University of California, San Diego

Who can join

18 and older, any sex, with Ulcerative Colitis or Crohn Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to compare the effectiveness and safety of a strategy of switching to an alternative targeted immunomodulator (TIM) therapy to treat to a target of endoscopic remission, versus continuing index TIM in patients with inflammatory bowel disease (IBD) (Crohn's disease or ulcerative colitis \[UC\]) in symptomatic remission with moderate to severe endoscopic inflammation despite optimization of index TIM in a real-world setting.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Treat-to-target of endoscopic remission in patients with inflammatory bowel disease in symptomatic remission on advanced therapies (QUOTIENT): rationale, design and protocol for an open-label, multicentre, pragmatic, randomised controlled trial.
Singh S, Nguyen JD, Fudman DI, Gerich ME, et al · · 2025 · cited 2× · PMID 40164445 · DOI 10.1136/bmjgast-2024-001615
Second United Arab Emirates consensus guidance on the diagnosis and management of inflammatory bowel disease.
Al Awadhi S, Al Hassani A, El Ouali S, Alam MB, et al · · 2025 · cited 1× · PMID 41024766 · DOI 10.3748/wjg.v31.i35.109882
Treat-to-Target in Inflammatory Bowel Diseases: Lessons from Screening in a Pragmatic Clinical Trial.
Hou JK, Nguyen J, Rodriguez-Gaytan J, Patel S, et al · · 2026 · PMID 41668798 · DOI 10.1093/crocol/otaf067

Verify or expand the search:

Other recruiting trials for Ulcerative Colitis

Currently open trials in the same condition.

NCT07185009 — A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Acti · Phase 3 · recruiting
NCT07265570 — Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA) · Phase 2 · recruiting
NCT07223424 — Patient Preference for Subcutaneous vs. Intravenous Immune Therapy · Phase 2 · recruiting
NCT06405087 — A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD · Phase 3 · recruiting
NCT07184996 — An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Activ · Phase 3 · recruiting

Other University of California, San Diego trials

Trials by the same sponsor.

NCT07342543 — Guided Physical Activity Counseling for Hypertension in Primary Care · NA · not yet recruiting
NCT06505317 — Artificial Intelligence for Early Detection of Peripheral Artery Disease · NA · not yet recruiting
NCT07211802 — CKM For Safe Use of SGLT2i in Type 1 Diabetes · Phase 3 · not yet recruiting
NCT07524751 — Culturally Adapted Pain Management for Indigenous Peoples · NA · not yet recruiting
NCT07518784 — Accurate Point of Care Liver Disease Diagnostics (Phase 2) · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05230173 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, San Diego
Last refreshed: 15 April 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05230173.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing